Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Mycosis Fungoides Clinical Trials

A listing of Mycosis Fungoides medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (4) clinical trials

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

PRIMARY OBJECTIVES: I. To evaluate the safety of brentuximab vedotin and rituximab in patients with lymphoid malignancies that are cluster of differentiation (CD) 30 positive (+) and/or Epstein-Barr virus (EBV)+, and to determine the recommended phase 2 dose (RP2D) of the combination. (Phase I) II. To evaluate the efficacy, as ...

Phase

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (recommended phase 2 dose, RP2D) of lenalidomide, when given in combination with fixed-dose durvalumab. (Phase 1) II. To assess the safety and tolerability of the lenalidomide/durvalumab regimen, and accompanying dose modification plan, by evaluation of toxicities including: type, frequency, severity, attribution, ...

Phase

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

PRIMARY OBJECTIVES: I. Evaluate the safety of pembrolizumab in combination with romidepsin. II. Estimate the response rate of the combination therapy in refractory or recurrent peripheral T-cell lymphoma (PTCL). SECONDARY OBJECTIVES: I. Estimate progression free survival (PFS). II. Estimate overall survival (OS). III. Estimate complete response (CR) and duration of ...

Phase

Pembrolizumab and Pralatrexate in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphomas

PRIMARY OBJECTIVES: I. Evaluate the safety and tolerability of a regimen combining pembrolizumab and pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). II. Establish the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combined pralatrexate and pembrolizumab regimen. III. Estimate the overall response ...

Phase